Meta Health (SGX:5DX) has amended its acquisition agreement for a 55% stake in Jas Medical Screening Centre, adjusting the terms for performance-based earn-out shares and contingent introducer shares, according to a Thursday filing on the Singapore Exchange.
Under the revised terms, shares will be issued if Jas Medical achieves net profits of at least SG$175,000 in 2025 and 2026, with adjustments linked to changes in Meta's share base.
Independent reviewers will verify the calculations. The company clarified that these amendments do not alter the deal's structure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.